- Home
- MAX vs BCYC Comparison
MAX vs BCYC Comparison
Compare MAX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- BCYC
- Stock Information
- Founded
- MAX 2014
- BCYC 2009
- Country
- MAX United States
- BCYC United Kingdom
- Employees
- MAX N/A
- BCYC N/A
- Industry
- MAX Industrial Machinery/Components
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- BCYC Health Care
- Exchange
- MAX Nasdaq
- BCYC Nasdaq
- Market Cap
- MAX 551.1M
- BCYC 565.5M
- IPO Year
- MAX 2020
- BCYC 2019
- Fundamental
- Price
- MAX $12.69
- BCYC $6.51
- Analyst Decision
- MAX Buy
- BCYC Buy
- Analyst Count
- MAX 6
- BCYC 11
- Target Price
- MAX $17.00
- BCYC $20.73
- AVG Volume (30 Days)
- MAX 570.7K
- BCYC 318.0K
- Earning Date
- MAX 10-29-2025
- BCYC 10-30-2025
- Dividend Yield
- MAX N/A
- BCYC N/A
- EPS Growth
- MAX N/A
- BCYC N/A
- EPS
- MAX N/A
- BCYC N/A
- Revenue
- MAX $1,123,093,000.00
- BCYC $28,339,000.00
- Revenue This Year
- MAX $27.56
- BCYC N/A
- Revenue Next Year
- MAX $10.79
- BCYC N/A
- P/E Ratio
- MAX N/A
- BCYC N/A
- Revenue Growth
- MAX 64.86
- BCYC N/A
- 52 Week Low
- MAX $7.33
- BCYC $6.10
- 52 Week High
- MAX $13.85
- BCYC $25.39
- Technical
- Relative Strength Index (RSI)
- MAX 61.96
- BCYC 36.29
- Support Level
- MAX $12.14
- BCYC $6.10
- Resistance Level
- MAX $13.85
- BCYC $9.08
- Average True Range (ATR)
- MAX 0.56
- BCYC 0.54
- MACD
- MAX 0.23
- BCYC -0.24
- Stochastic Oscillator
- MAX 67.49
- BCYC 12.92
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.